HINDUSTAN UNILEVER LTD

FMCG

Volume, margin disappoint

Fears of increase in royalty come true

HUL reported weakest volume growth in 11 quarters at 5% YoY, well below our expectation of 8% YoY, as slowdown in discretionary segments and price increase in low priced SKUs in select brands impacted demand. Faster growth in low margin S&D segment impacted margin mix with lower than expected expansion in EBITDA margin (10 bps vs. 60 bps expected). Consequently, earnings growth of 15% YoY was slightly below our expectation of 18%.

A phased increase in royalty by 1.75ppt to 3.15% over FY14-18 coupled with increase in tax rate closer to marginal tax rate by FY15 will impact earnings growth. We forecast 13% earnings CAGR over FY13-15, even as we expect volume concerns to ebb with likely recovery to 7% in FY14.

23 JAN 2013 / Quarterly Update

HOLD

Target Price: Rs 510

CMP : Rs 482 Potential Upside : 6%

Relative to Sector : Outperformer

MARKET DATA

No. of Shares : 2,162mn

Free Float : 48%

Market Cap : Rs1,041bn

52-week High / Low : Rs571 / Rs370

Avg. Daily vol. (6mth) : 2.4 mn shares

Bloomberg Code : HUVR IB Equity

 Promoters Holding
 : 52%

 FII / DII
 : 22% / 9%

 BSE Code
 : 500696

NSE Code : HINDUNILVR

Personal Products (PP) slowdown impacts volume and mix

Personal products yet again posteda sub-15% growth (up 13% YoY in Q3 vs. 12% growth in Q2). However, we believe this is just a mid-cycle slowdown and hence recovery is likely going forward (led by new launches and pick in demand environment). This will also lead to improved margin mix for HUL.

S&D margin to improve over 100 bps in FY14

Consistent price hikes coupled with moderating input cost (PFAD – palm oil derivative – down 30% YoY from its peak) is expected to drive over 100 bps improvement in S&D segment. However, rise in competitive intensity is likely to drive higher media spends.

Maintain HOLD with Mar' 14 TP of Rs 510 (6% upside)

We roll forward our valuation to FY15E earnings and value HUL at 27x (3-year mean), which is justified given slowdown in earnings momentum (due to higher tax rate and royalty).

FINANCIAL SUMMARY (Standalone)

Y/E March	FY12	FY13E	FY14E	FY15E
Sales (Rs mn)	217,356	254,427	291,127	333,671
Adj PAT (Rs mn)	25,602	32,116	36,280	40,958
Con. EPS* (Rs.)	-	15.0	17.3	19.5
EPS (Rs.)	11.8	14.9	16.8	18.9
Change YOY (%)	19.8	25.4	13.0	12.9
P/E (x)	34.6	32.4	28.7	25.4
RoE (%)	83.0	108.2	127.4	109.5
RoCE (%)	76.7	93.9	112.1	102.8
EV/EBITDA (x)	25.8	25.2	20.9	17.9
DPS	7.0	17.0	11.0	12.5

Source: *Consensus broker estimates, Company, AXIS Capital estimates

KEY DRIVERS

	FY12	FY13E	FY14E	FY15E
Volume growth (%)	10	7	7	8
Dom. price growth (%)	8	10	8	7
A&P spend (% of net	12.2	12.8	12.8	12.8
Royalty (% of net sales)	1.3	1.4	1.9	2.3

PRICE PERFORMANCE



Axis Securities Ltd 01



Exhibit 1: Results update

	Quarter ended			12 months ended				
(Rs. mn)	Dec-12	Dec-11	% Chg	Sep-12	% Chg	FY13e	FY12	% Chg
Net Income	66,548	59,555	11.7	63,108	5.5	261,068	221,439	17.9
EBIDTA	10,888	9,705	12.2	9,767	11.5	40,260	33,066	21.8
Other income	1,337	801	67.0	1,488	(10.1)	5,674	2,507	126.3
PBIDT	12,225	10,506	16.4	11,255	8.6	45,934	35,574	29.1
Depreciation	593	568	4.3	577	2.8	2,338	2,183	7.1
Interest	75	5	-	63	19.0	196	12	-
PBT	11,557	9,933	16.3	10,615	8.9	43,400	33,379	30.0
Tax	2,771	2,271	22.0	2,561	8.2	11,284	7,776	45.1
Other provisions	0	0	-	0	-	0	(1)	-
Adjusted PAT	8,786	7,662	14.7	8,053	9.1	32,116	25,602	25.4
Extra ordinary income/ (exp.)	(73)	(124)	(41.2)	16	-	5,866	1,311	347.4
Reported PAT	8,714	7,538	15.6	8,069	8.0	37,982	26,914	41.1
No. of shares (mn)	2,161	2,161	-	2,161	-	2,162	2,162	-
EBIDTA margin (%)	16.4	16.3	-	15.5	-	15.4	14.9	-
PBIDT margin (%)	18.4	17.6	-	17.8	-	17.6	16.1	-
EPS - annualized (Rs.)	16.3	14.2	14.7	14.9	9.1	14.9	11.8	25.4

Source: Company, Axis Capital

Volume growth deceleration - structuralor transitional?

Underlying domestic volume growth of 5% in Q3FY13 was the weakest since March2010 (i.e. 11 quarters). According to the management, growth deceleration was due to a weakness in discretionary categories such as food and personal care products (35% of revenue; 50% of EBIT). Growth in personal products (PP) stood at 12% in the last 2 quarters vs. average growth of 16%. Similarly packed foods segment grew by 8% in Q3FY13 as against 16% growth in FY12.

We believe a large part of this slowdown is more transitional in nature rather than structural. Demand growth in discretionary categories like foods has been hit across the board due to squeeze in disposable income. Falling inflation rate and resultant reduction in interest rates could act as useful triggers for demand recovery. The management also mentioned that new packaging norms, pricing actions (in Fair and Lovely), and slowdown in modern trade were responsible for weakvolume growth in PP segment. However, unit growth to consumers was strong as a result of sustained rural demand and recovery in off-take by Canteen Stores Department.

We believe this mid-cycle slowdown will be followed by a gradual demand recovery leading to ~7% volume growth in FY14.

50 bps p.a. increase in royalty charge to impact earnings by 3%

HUL shall pay increased royalty in phases with 50bps rise in FY14 and overall increase of 1.75% over FY14-18. Consequently, the royalty payment shall increase from 1.4% currently to 3.15% of net sales by FY18. Increase in royalty payment is generally perceived as a means for parent to maximize return from its subsidiary. In fact, Unilever Indonesia share price corrected by 11% since 12th Dec 2012 as the company announced that it had signed new agreements with Unilever Plc that will gradually increase its royalty costs from the current 3.5% (2% royalty, 1.5% services) of revenue from global brands to a maximum of 8% of this revenue when the agreements are fully applied in 2015.



HUL currently pays 1.4% (of net sales) as royalty under various heads (includes trademarks license agreement and technology license agreement), which is lower than most other listed regional subsidiaries of Unilever such as Unilever Nigeria (Royalty at 2.5% of net sales) and Unilever Pakistan (royalty at 3.5% of net sales). Even most MNC FMCG companies such as Nestle (3.4% of net revenue in CY11) and Colgate (5.4% of net revenue in FY12) pay higher royalty than HUL. Thus, the increase in royalty payment was inevitable, but the timing may have surprised investors. While 0.5% p.a. increase in royalty charge could have an impact of ~3% on earnings, we believe the company will take pricing actions that could reduce the impact. Thus, we have downgraded our earnings estimate by 1% for FY14.

Soaps and Detergents (S&D) margin can improve further: Detergents margin, which had hit a trough in Q4FY11, has consistently improved aided by price hikes and reduced intensity in media spend. According to the management, while gross margin for S&D segment has continued to improve due to fall in key input cost (PFAD down by 30% from its April'12 peak), the segmental EBIT margin contracted by 100 bps in Q3FY13 due to increase in competitive media spend. In our opinion, while margin in soaps segment has risen well over historical mean, the detergent margin is still at its trough (refer our Consumer Insightsnoteon Fabric wash segment titledBrighter hues dated 30th Nov 2012). With further pricing actions and stable cost environment (LAB up 3% YoY and soda ash up 16% YoY in Q3FY13), we expect S&D margin to improve by over 100 bps in FY14E.

Expected slowdown in earnings momentum justifies lower valuation

HUL has corrected by 14% over last 3 monthson concerns over volume being impacted by lower discretionary spends and higher royalty to parent. As earnings momentum is likely to slow down (13% CAGR over FY13E-15E vs. 23% CAGR over FY11-13) due to higher tax rate and increase in royalty payment, we believe HUL would find it difficult to sustain current premium valuation (29x 1-yr fwd) and PE multiple would seek a reasonable level in coming months. Hence we have valued HUL based on target P/E of 27x (3-year mean). Our March '14target price of

Rs 510 implies 6% upside from CMP. Maintain HOLD.

Exhibit 2: Revenue growth trend

% of Q3FY13		Sales Growth YoY (%)						
	Revenue	Q1'12	Q2'12	Q3'12	Q4'12	Q1'13	Q2'13	Q3'13
Soaps and Detergents	48	12.9	21.9	20.8	28.6	23.7	22.3	19.8
Personal Products	31	15.9	14.0	9.6	17.3	16.7	12.1	13.0
Beverages	12	13.3	14.8	11.4	7.8	7.4	10.0	18.2
Packaged foods	5	18.0	21.1	13.6	9.8	17.3	10.2	7.7

Source: Company, Axis Capital




Exhibit 3: EBIT margin trend

	% of Q3FY13			EBIT m	argin trend ((%)		
	EBIT	Q1'12	Q2'12	Q3'12	Q4'12	Q1'13	Q2'13	Q3'13
Soaps and Detergents	36	9.2	12.4	13.4	11.3	12.2	14.3	12.4
Personal Products	53	26.0	25.5	26.8	26.3	25.8	24.2	28.3
Beverages	13	12.4	13.4	15.7	14.4	14.5	14.3	17.7
Packaged foods & Others	0	4.7	5.0	(1.9)	(1.1)	5.7	0.2	(0.8)

Source: Company, Axis Capital

Exhibit 4: Domestic volumegrowth vs. stock price **Exhibit 5:**




Source: Company, Axis Capital

Exhibit 5: Pricing trend




Source: Company, Axis Capital

Exhibit 6: GPM trend




Source: Axis Capital

Exhibit 7: Commodity cost trend



Source: Bloomberg, Axis Capital





Source: Bloomberg, Axis Capital



FINANCIAL SUMMARY (Standalone)

Profit & Loss (Rsmn)

Y/E March	FY12	FY13E	FY14E	FY15E
Net sales	217,356	254,427	291,127	333,671
Other operating income	4,083	6,641	7,628	8,742
Total operating income	221,439	261,068	298,754	342,413
Cost of goods sold	(117,378)	(136,754)	(153,100)	(174,680)
Gross profit	104,062	124,314	145,654	167,733
Gross margin (%)	47.9	48.9	50.0	50.3
Total operating expenses	(70,996)	(84,054)	(97,236)	(111,814)
EBITDA	33,066	40,260	48,419	55,919
EBITDA margin (%)	15.2	15.8	16.6	16.8
Depreciation	(2,183)	(2,338)	(2,721)	(3,032)
EBIT	30,884	37,922	45,698	52,887
Net interest	(12)	(196)	-	-
Other income	2,507	5,674	4,000	4,800
Profit before tax	33,379	43,400	49,698	57,687
Total taxation	(7,776)	(11,284)	(13,418)	(16,729)
Tax rate (%)	23.3	26.0	27.0	29.0
Profit after tax	25,602	32,116	36,280	40,958
Minorities	-	-	-	-
Profit/ Loss associate co(s)	-	-	-	-
Adjusted net profit	25,602	32,116	36,280	40,958
Adj. PAT margin (%)	11.8	12.6	12.5	12.3
Net non-recurring items	1,311	5,866	1,000	1,050
Reported net profit	26,914	37,982	37,280	42,008

Balance Sheet (Rsmn)

Y/E March	FY12	FY13E	FY14E	FY15E
Paid-up capital	2,162	2,162	2,162	2,162
Reserves & surplus	32,968	22,092	30,553	39,899
Net worth	35,129	24,254	32,715	42,061
Borrowing	9,966	11,450	13,101	15,016
Other non-current liabilit	ies -	-	-	-
Total liabilities	109,583	117,704	131,416	153,895
Gross fixed assets	38,117	42,617	47,617	53,617
Less: Depreciation	(16,642)	(18,980)	(21,700)	(24,732)
Net fixed assets	21,475	23,637	25,916	28,884
Add: Capital WIP	2,155	1,500	1,800	2,000
Total fixed assets	23,629	25,137	27,716	30,884
Other Investment	-	-	-	-
Inventory	25,167	30,560	34,986	40,709
Debtors	6,790	8,369	9,286	10,330
Cash & bank	18,300	12,018	10,856	16,399
Loans & advances	5,210	6,361	7,424	8,675
Current liabilities	64,487	82,001	85,600	96,819
Net current assets	(5,058)	(19,858)	(17,225)	(14,033)
Other non-current assets	2,142	2,042	1,942	1,842
Total assets	109,583	117,704	131,416	153,895

Cash flow (Rsmn)

Y/E March	FY12	FY13E	FY14E	FY15E
Profit before tax	33,379	43,400	49,698	57,687
Depreciation & Amortisation	(2,183)	(2,338)	(2,721)	(3,032)
Chg in working capital	2,036	9,490	(2,706)	3,301
Cash flow from operations	28,842	31,925	24,766	33,849
Capital expenditure	(2,522)	(3,846)	(5,300)	(6,200)
Cash flow from investing	(4,671)	4,469	1,328	2,342
Equity raised/ (repaid)	336	-	-	-
Debt raised/ (repaid)	-	-	-	-
Dividend paid	(17,546)	(42,992)	(27,819)	(31,612)
Cash flow from financing	(17,223)	(42,796)	(27,818)	(31,612)
Net chg in cash	6,948	(6,402)	(1,725)	4,579

FMCG

		, ,	, ,	
Key ratios				
Y/E March	FY12	FY13E	FY14E	FY15E
OPERATIONAL				
FDEPS (Rs)	11.8	14.9	16.8	18.9
CEPS (Rs)	13.5	18.7	18.5	20.8
DPS (Rs)	7.0	17.0	11.0	12.5
Dividend payout ratio (%)	56.1	96.7	63.8	64.3
GROWTH				
Net sales (%)	12.1	17.1	14.4	14.6
EBITDA (%)	21.6	21.8	20.3	15.5
Adj net profit (%)	19.9	25.4	13.0	12.9
FDEPS (%)	19.8	25.4	13.0	12.9
PERFORMANCE				
RoE (%)	83.0	108.2	127.4	109.5
RoCE (%)	76.7	93.9	112.1	102.8
EFFICIENCY				
Asset turnover (x)	38.4	7,053.6	(544.6)	108.1
Sales/ total assets (x)	2.1	2.2	2.3	2.3
Working capital/ sales (x)	(0.1)	(0.1)	(0.1)	(0.1)
Receivable days	11.4	12.0	11.6	11.3
Inventory days	48.8	50.5	51.0	51.9
Payable days	100.2	99.1	96.4	94.3
FINANCIAL STABILITY				
Total debt/ equity (x)	0.3	0.4	0.5	0.4
Net debt/ equity (x)	(1.0)	(0.9)	(1.1)	(1.0)
Current ratio (x)	0.9	0.8	0.8	0.9
Interest cover (x)	2,490.6	193.5	-	-
VALUATION				
PE (x)	34.6	32.4	28.7	25.4
EV/ EBITDA (x)	25.8	25.2	20.9	17.9
EV/ Net sales (x)	3.9	4.0	3.5	3.0
PB (x)	25.2	42.9	31.8	24.7
Dividend yield (%)	(1.7)	(3.5)	(2.3)	(2.6)
Free cash flow yield (%)	3.0	2.7	1.9	2.7



320 City Centre,

570, M.G. Road,

Indore (M.P.) - 452 001

(+91-0731) 3916601

Pune (Shivajinagar)

(+91-20) 3054 7125

1248 A, Goodluck Chowk

Gymkhana, Shivajinagar, Pune – 411 004

Regd Office: Axis House, C2, Wadia International Centre, P.B Marg, Worli, Mumbai 400 025, India. Corporate Office: 201-A Laxmi Towers, Bandra-Kurla Complex, Bandra (E), Mumbai - 400 051 (+91-22) 6680 3600(
Axis Securities Lim	Axis Securities Limited Branch Details				
Mumbai Bangalore					
201-A Laxmi Towers, Bandra-Kurla Complex, Bandra (E), Mumbai - 400 051 (+91-22) 6680 3600	Unit No.10/3, Ground Floor, Empire Infantry, 29 Infantry Road, Bangalore − 560 001 (+91-80) 4033 3200 - 212				
Baroda	Chennai				
GF 9 Silverline, Sayajiganj, – 390 005 (+91-265) 302 6945	11 Vijay Delux Apts., 7/4 First CIT Colony, Mylapore, Chennai– 600 004 (+91-44) 3918 4228 / 3989 3626				
Delhi Unit No. 815 & 816, Ambadeep Building, Kasturba Gandhi Marg, New Delhi - 110001 (+91-11) 9818263885	Hyderabad 217 B Maheshwari Chambers Somajiguda, − 500 082 (+91-40) 3065 8501				
Indore Kolkata					

Axis Securities Limited *

Website: www.axissecurities.in • Email: directresearch@enam.com

Om Towers, 4th Floor, 401,

Toral Building, Office no 308,

3rd Floor, Near Galaxy Hotel, – 360001

32 Chowringhee Road

(+91-33) 4005 6201

(+91-281) 3200170

Kolkata - 700 071

Raikot

This document has been prepared by AXIS Securities Ltd * – Privileged Client Group. Affiliates of AXIS Securities Ltd * focused on Institutional Equities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating and target price of the Affiliates research report.

The views expressed / recommendations made in this report are based on Technical Analysis techniques and could be at variance with the company's / group's views based on fundamental research.

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent.

This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgement by any recipient.

Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions - including those involving futures, options and other derivatives as well as non investment grade securities - involve substantial risk and are not suitable for all investors.

AXIS Securities Ltd * has not independently verified all the information given in this document. Accordingly, no representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document.

The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval.

AXIS Securities Ltd*, its affiliates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document.

This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of AXIS Securities Ltd*. The views expressed are those of the analyst and the Company may or may not subscribe to all the views expressed therein.

This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. Neither this document nor any copy of it may be taken or transmitted into the United State (to U.S. Persons), Canada, or Japan or distributed, directly or indirectly, in the United States or Canada or distributed or redistributed in Japan or to any resident thereof.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject AXIS Securities Ltd* to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information.

Copyright in this document vests exclusively with AXIS Securities Ltd *.

^{*} The name of the company has changed to Axis Securities Limited in the records of Registrar of Companies, Mumbai. Awaiting approval for change of name from Exchanges and SEBI.



23 JAN 2013 / Quarterly Update HINDUSTAN UNILEVER LTD

Disclaimer of Axis Capital Limited:

The document has been prepared by Axis Securities Limited (formerly Enam Securities Direct Private Limited) (the company). Axis Capital Limited (hereinafter referred to as "ACL") has been permitted by the company to use the same and circulate it to its clients. This document is not, and should not be construed, as an offer to sell or solicitation to buy any securities in any jurisdiction. This document may not be reproduced, distributed or published, in whole or in part, without prior permission from the Company. ACL does not guarantee that the document is complete or accurate and it should not be relied on as such. Investors should make his/her own research, analysis and investigation as he/she deems fit and reliable to come at an independent evaluation of an investment (including the merits, demerits and risks involved), and should further take opinion of their own consultants, advisors to determine the advantages and risks of investment. ACL, its affiliates, group companies, directors, employees, agents or representatives shall not be held responsible, liable for any kind of consequential damages whether direct, indirect, special or consequential including but not limited to losses, lost revenue, lost profits, notional losses that may arise from or in connection with the use of the information in the document.

Registered office address

Axis House, 8th Floor, Wadia International Center, Pandurang Budhkar Marg, Worli, Mumbai 400 025.

SEBI Registration no: NSE (CM)-INB 231387235, (FO)-INF 231387235, (CDS)-INE 231387235,BSE(CM)-INB 011387330,(FO)-INF011387330, ARN No. 51485

Main/Dealing office

Solaris,"C" Bldg., 6th floor, Opp. L&T Gate No. 6, Saki Vihar Road, Powai, Mumbai-400072, Tel No.-18001030808,

Compliance Officer Details:

Name: Anand Shaha, E-Mail ID: compliance.officer@axisdirect.in,Tel No: 022-40754152.